TALEN

TALEN1-apoba

ID

ZDB-TALEN-220718-1

Name

TALEN1-apoba

Previous Names

None

Target

apoba (1)

Target Sequence 1

5' - TACAGCTAACCTCAAGAA - 3'

Target Sequence 2

5' - TGTTTTTGTACCTGGCA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

None

Genome Resources

None

Target Location

Constructs

No data available

Genomic Features

Genomic Feature	Affected Genomic Regions
wz26	apoba

Expression

Gene expression in Wild Types + TALEN1-apoba

No data available

Phenotype

Phenotype resulting from TALEN1-apoba

No data available

Phenotype of all Fish created by or utilizing TALEN1-apoba

Phenotype	Fish	Conditions	Figures
whole organism apoba expression decreased amount, abnormal	apoba^wz26/wz26	standard conditions	Figure 1 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis increased occurrence, abnormal	apoba^wz26/wz26; y1Tg	standard conditions	Figure 4 from Templehof et al., 2021
subintestinal venous plexus Notch signaling pathway increased occurrence, abnormal	apoba^wz26/wz26; y1Tg	standard conditions	Figure 4 from Templehof et al., 2021
liver bilaterally paired, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
liver hepatocyte has extra parts of type hepatocyte lipid droplet, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis increased occurrence, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 4 from Templehof et al., 2021
liver tfa expression spatial pattern, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
liver fatty, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis increased occurrence, abnormal	apoba^wz26/wz26 + MO1-apobb.1	chemical treatment by environment: oleate	Figure 4 from Templehof et al., 2021
determination of liver left/right asymmetry decreased process quality, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
subintestinal venous plexus has extra parts of type subintestinal venous plexus angiogenic sprout, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 4 from Templehof et al., 2021
intestinal epithelium has fewer parts of type goblet cell, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 3 from Templehof et al., 2021
liver prox1a expression spatial pattern, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis occurrence, ameliorated	apoba^wz26/wz26 + MO1-apobb.1	chemical treatment by injection: low-density lipoprotein	Figure 4 from Templehof et al., 2021
subintestinal venous plexus has number of subintestinal venous plexus angiogenic sprout, ameliorated	apoba^wz26/wz26 + MO1-apobb.1	chemical treatment by injection: low-density lipoprotein	Figure 4 from Templehof et al., 2021
liver fabp10a expression decreased amount, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
subintestinal venous plexus has extra parts of type subintestinal venous plexus angiogenic sprout, abnormal	apoba^wz26/wz26 + MO1-apobb.1	chemical treatment by environment: oleate	Figure 4 from Templehof et al., 2021
whole organism cholesterol decreased amount, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 1 from Templehof et al., 2021
liver decreased size, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
whole organism triglyceride decreased amount, abnormal	apoba^wz26/wz26 + MO1-apobb.1	standard conditions	Figure 1 from Templehof et al., 2021
whole organism apoba expression decreased amount, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
yolk opaque, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
trunk curved dorsal, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
yolk edematous, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
whole organism apobb.1 expression decreased amount, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
heart edematous, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
yolk increased volume, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
blood lipid decreased amount, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
whole organism triglyceride decreased amount, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
whole organism cholesterol decreased amount, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25	standard conditions	Figure 1 from Templehof et al., 2021
subintestinal venous plexus has extra parts of type subintestinal venous plexus angiogenic sprout, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25; y1Tg	standard conditions	Figure 4 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis increased occurrence, abnormal	apoba^wz26/wz26; apobb.1^wz25/wz25; y1Tg	standard conditions	Figure 4 from Templehof et al., 2021
liver EGFP expression decreased amount, abnormal	apoba^wz26/wz26; as3Tg + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
liver decreased size, abnormal	apoba^wz26/wz26; as3Tg + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
liver Notch signaling pathway decreased occurrence, abnormal	apoba^wz26/wz26; ia12Tg + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
intestine EGFP expression increased amount, abnormal	apoba^wz26/wz26; ia12Tg + MO1-apobb.1	standard conditions	Figure 3 from Templehof et al., 2021
liver EGFP expression decreased amount, abnormal	apoba^wz26/wz26; ia12Tg + MO1-apobb.1	standard conditions	Figure 2 from Templehof et al., 2021
intestine Notch signaling pathway increased occurrence, abnormal	apoba^wz26/wz26; ia12Tg + MO1-apobb.1	standard conditions	Figure 3 from Templehof et al., 2021
subintestinal venous plexus Notch signaling pathway increased occurrence, abnormal	apoba^wz26/wz26; ia12Tg; um13Tg + MO1-apobb.1	standard conditions	Figure 4 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis increased occurrence, abnormal	apoba^wz26/wz26; ia12Tg; um13Tg + MO1-apobb.1	standard conditions	Figure 4 from Templehof et al., 2021
intestine lumen increased diameter, abnormal	apoba^wz26/wz26; pd1034Tg + MO1-apobb.1	standard conditions	Figure 3 from Templehof et al., 2021
intestinal epithelium has fewer parts of type intestinal epithelium microvillus, abnormal	apoba^wz26/wz26; pd1034Tg + MO1-apobb.1	standard conditions	Figure 3 from Templehof et al., 2021
intestine shape, abnormal	apoba^wz26/wz26; pd1034Tg + MO1-apobb.1	standard conditions	Figure 3 from Templehof et al., 2021
subintestinal venous plexus has extra parts of type subintestinal venous plexus angiogenic sprout, abnormal	apoba^wz26/wz26; y1Tg + MO1-apobb.1	standard conditions	Figure 4 from Templehof et al., 2021
subintestinal venous plexus sprouting angiogenesis increased occurrence, abnormal	apoba^wz26/wz26; y1Tg + MO1-apobb.1	standard conditions	Figure 4 from Templehof et al., 2021

Citations